CDXC vs. MDWD, FTLF, BTMD, NAII, ACB, MTEX, MNMD, USNA, INO, and GLUE
Should you be buying ChromaDex stock or one of its competitors? The main competitors of ChromaDex include MediWound (MDWD), FitLife Brands (FTLF), biote (BTMD), Natural Alternatives International (NAII), Aurora Cannabis (ACB), Mannatech (MTEX), Mind Medicine (MindMed) (MNMD), USANA Health Sciences (USNA), Inovio Pharmaceuticals (INO), and Monte Rosa Therapeutics (GLUE). These companies are all part of the "medical" sector.
ChromaDex (NASDAQ:CDXC) and MediWound (NASDAQ:MDWD) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, valuation, media sentiment, risk, profitability and community ranking.
ChromaDex has higher revenue and earnings than MediWound. ChromaDex is trading at a lower price-to-earnings ratio than MediWound, indicating that it is currently the more affordable of the two stocks.
ChromaDex has a beta of 1.96, indicating that its stock price is 96% more volatile than the S&P 500. Comparatively, MediWound has a beta of 0.81, indicating that its stock price is 19% less volatile than the S&P 500.
ChromaDex has a net margin of -5.91% compared to MediWound's net margin of -35.94%. ChromaDex's return on equity of -17.81% beat MediWound's return on equity.
In the previous week, ChromaDex had 3 more articles in the media than MediWound. MarketBeat recorded 5 mentions for ChromaDex and 2 mentions for MediWound. ChromaDex's average media sentiment score of 0.74 beat MediWound's score of 0.30 indicating that ChromaDex is being referred to more favorably in the media.
ChromaDex currently has a consensus price target of $5.87, indicating a potential upside of 55.20%. MediWound has a consensus price target of $32.00, indicating a potential upside of 71.58%. Given MediWound's higher probable upside, analysts clearly believe MediWound is more favorable than ChromaDex.
ChromaDex received 144 more outperform votes than MediWound when rated by MarketBeat users. Likewise, 63.94% of users gave ChromaDex an outperform vote while only 62.28% of users gave MediWound an outperform vote.
15.4% of ChromaDex shares are owned by institutional investors. Comparatively, 46.8% of MediWound shares are owned by institutional investors. 10.6% of ChromaDex shares are owned by company insiders. Comparatively, 9.2% of MediWound shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
ChromaDex beats MediWound on 12 of the 16 factors compared between the two stocks.
Get ChromaDex News Delivered to You Automatically
Sign up to receive the latest news and ratings for CDXC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CDXC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ChromaDex Competitors List
Related Companies and Tools
